![Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41533-020-00205-9/MediaObjects/41533_2020_205_Fig1_HTML.png)
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
![Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41533-020-00205-9/MediaObjects/41533_2020_205_Fig2_HTML.png)
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
![Petition · Legal requirement for strong warning about risk of Singulair and generic Montelukast · Change.org Petition · Legal requirement for strong warning about risk of Singulair and generic Montelukast · Change.org](https://assets.change.org/photos/1/ej/na/rMEjNaDXfHtVBtS-1600x900-noPad.jpg?1598148474)
Petition · Legal requirement for strong warning about risk of Singulair and generic Montelukast · Change.org
![Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial - The Lancet Respiratory Medicine Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial - The Lancet Respiratory Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1bad0a7d-fefb-4906-9c96-b8f1b92fa38f/gr1.gif)
Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial - The Lancet Respiratory Medicine
![Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) - World Allergy Organization Journal Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) - World Allergy Organization Journal](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/73f76217-96e0-4631-be9f-ed109fdab4d1/gr1.jpg)
Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) - World Allergy Organization Journal
![PDF) Development of an efficient and practical approach for the synthesis of Montelukast Sodium Intermediate PDF) Development of an efficient and practical approach for the synthesis of Montelukast Sodium Intermediate](https://i1.rgstatic.net/publication/348557868_Development_of_an_efficient_and_practical_approach_for_the_synthesis_of_Montelukast_Sodium_Intermediate/links/606baa7592851c91b1a6c32b/largepreview.png)